The mTOR is a validated target in many human cancers, and rapamycin analogs (rapalogs) have shown promising results in various tumor types, including non-Hodgkin's lymphoma, sarcoma, glioblastoma and endometrial cancer. The gene discussed is MTOR; the disease is sarcoma.